These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 153449)

  • 41. Deductibles and co-payment.
    Lewis RF
    Wis Med J; 1981 Mar; 80(3):7-8. PubMed ID: 7281711
    [No Abstract]   [Full Text] [Related]  

  • 42. Survey shows hospitals expand generic drug use.
    Jaffe MO
    Health Care Week; 1979 Feb; 2(30):1, 3. PubMed ID: 10240113
    [No Abstract]   [Full Text] [Related]  

  • 43. Generic drugs: an overview.
    Helgeland D
    S D Med; 2006 Apr; 59(4):161-3. PubMed ID: 16681165
    [No Abstract]   [Full Text] [Related]  

  • 44. The precarious state of Medicaid.
    Murer CG
    Rehab Manag; 2008 Jul; 21(6):37-9. PubMed ID: 18767610
    [No Abstract]   [Full Text] [Related]  

  • 45. Medical school, state settle Medicaid billing policy dispute.
    Am Med News; 1979 Mar; 22(9):3. PubMed ID: 10297403
    [No Abstract]   [Full Text] [Related]  

  • 46. Medicare program--cost to related organizations: proposed rule.
    Fed Regist; 1979 Jan; 44(19):5479-80. PubMed ID: 10297328
    [No Abstract]   [Full Text] [Related]  

  • 47. Departicipating from Medicare and Medicaid programs.
    Schulte DJ
    Mich Med; 2007; 106(6):7. PubMed ID: 18078135
    [No Abstract]   [Full Text] [Related]  

  • 48. Medicaid reimbursement. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-13. PubMed ID: 19297676
    [No Abstract]   [Full Text] [Related]  

  • 49. Medicaid issues.
    Weston SN
    J S C Med Assoc; 1997 Jun; 93(6):205. PubMed ID: 9197108
    [No Abstract]   [Full Text] [Related]  

  • 50. M.D.'s update on generic.
    Kellogg N
    Leg Aspects Med Pract; 1978 May; 6(5):19-22. PubMed ID: 703469
    [No Abstract]   [Full Text] [Related]  

  • 51. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
    Paul SH
    Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270
    [No Abstract]   [Full Text] [Related]  

  • 52. Managing Medicaid drug expenditures.
    Sudovar SG; Rein SD
    J Health Hum Resour Adm; 1978 Nov; 1(2):200-30. PubMed ID: 10308767
    [No Abstract]   [Full Text] [Related]  

  • 53. Michigan's provider administrative review process.
    J Medicaid Manage; 1977; 1(1):24-7. PubMed ID: 10297553
    [No Abstract]   [Full Text] [Related]  

  • 54. Blues test capitation payment plan.
    LaViolette S
    Mod Healthc; 1980 Jun; 10(6):9. PubMed ID: 10247386
    [No Abstract]   [Full Text] [Related]  

  • 55. Third party reimbursement aspects of physician compensation.
    McKibben MS
    Top Health Care Financ; 1978; 4(3):35-57. PubMed ID: 345523
    [No Abstract]   [Full Text] [Related]  

  • 56. How does Medicare calculate reimbursement to hospitals for "guarantee arrangements" with emergency room physicians?
    Girad B
    Hosp Forum; 1976 May; 18(14):11. PubMed ID: 10297470
    [No Abstract]   [Full Text] [Related]  

  • 57. Insurance reimbursement policies and AIDS home healthcare: public and private financing mechanisms.
    Hanley BE
    AIDS Public Policy J; 1996; 11(2):89-103. PubMed ID: 10915242
    [No Abstract]   [Full Text] [Related]  

  • 58. "Sole community provider exemption": a status report.
    Manley MA
    Hosp Forum; 1981; 24(5):38. PubMed ID: 10298248
    [No Abstract]   [Full Text] [Related]  

  • 59. The Medicaid question: will dwindling reimbursement destroy the quality of medical care?
    Farrell K
    Mich Med; 1999 May; 98(5):24-32. PubMed ID: 10424085
    [No Abstract]   [Full Text] [Related]  

  • 60. Generic drug equivalents: opening Pandora's Rx.
    Regulation; 1979; 3(3):4-5. PubMed ID: 10242344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.